Published in Cancer Immunol Immunother on December 02, 2008
Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst (2012) 2.09
Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst (2010) 1.89
Identification and targeting of cancer stem cells. Bioessays (2009) 1.44
Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell lines. Breast Cancer Res (2009) 1.42
Musashi1 regulates breast tumor cell proliferation and is a prognostic indicator of poor survival. Mol Cancer (2010) 1.31
Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. Br J Cancer (2011) 1.23
Cooperation of Notch and Ras/MAPK signaling pathways in human breast carcinogenesis. Mol Cancer (2009) 1.20
The immune system and inflammation in breast cancer. Mol Cell Endocrinol (2013) 1.12
New promising drug targets in cancer- and metastasis-initiating cells. Drug Discov Today (2010) 0.99
Artemin Reduces Sensitivity to Doxorubicin and Paclitaxel in Endometrial Carcinoma Cells through Specific Regulation of CD24. Transl Oncol (2010) 0.98
Interplay of Stem Cell Characteristics, EMT, and Microtentacles in Circulating Breast Tumor Cells. Cancers (Basel) (2013) 0.94
Immunotherapy of radioresistant mammary tumors with early metastasis using molecular chaperone vaccines combined with ionizing radiation. J Immunol (2013) 0.93
The role of cancer stem cells in breast cancer initiation and progression: potential cancer stem cell-directed therapies. Oncologist (2012) 0.92
Notch signaling modulates MUC16 biosynthesis in an in vitro model of human corneal and conjunctival epithelial cell differentiation. Invest Ophthalmol Vis Sci (2011) 0.92
Immunotargeting of cancer stem cells. Contemp Oncol (Pozn) (2015) 0.85
Created Gli-1 duplex short-RNA (i-Gli-RNA) eliminates CD44 Hi progenitors of taxol-resistant ovarian cancer cells. Oncol Rep (2010) 0.84
Recent advances in therapeutic cancer vaccines. Cancer Biother Radiopharm (2012) 0.83
Role of Numb expression and nuclear translocation in endometrial cancer. Oncol Lett (2015) 0.79
Novel therapies against aggressive and recurrent epithelial cancers by molecular targeting tumor- and metastasis-initiating cells and their progenies. Anticancer Agents Med Chem (2010) 0.79
Nanomedicine-Mediated Therapies to Target Breast Cancer Stem Cells. Front Pharmacol (2016) 0.76
Necrosis and apoptosis in Trichinella spiralis-mediated tumour reduction. Cent Eur J Immunol (2015) 0.75
A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers. Oncotarget (2016) 0.75
Immune targeting of cancer stem cells in gastrointestinal oncology. J Gastrointest Oncol (2016) 0.75
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Identification and expansion of human colon-cancer-initiating cells. Nature (2006) 24.44
Identification of a cancer stem cell in human brain tumors. Cancer Res (2003) 24.02
Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res (2005) 13.89
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst (2008) 11.93
Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature (1998) 10.58
The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst (2006) 10.06
Asymmetric and symmetric stem-cell divisions in development and cancer. Nature (2006) 7.32
Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation. Nat Rev Genet (2008) 7.30
Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 5.85
A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1. Mol Cell (2000) 5.56
Notch signalling regulates stem cell numbers in vitro and in vivo. Nature (2006) 5.49
Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res (2006) 5.21
BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci U S A (2008) 4.79
IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest (2007) 4.71
Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane. Cell (1997) 3.47
The endocytic protein alpha-Adaptin is required for numb-mediated asymmetric cell division in Drosophila. Dev Cell (2002) 3.16
Mammalian numb proteins promote Notch1 receptor ubiquitination and degradation of the Notch1 intracellular domain. J Biol Chem (2003) 2.94
Numb controls integrin endocytosis for directional cell migration with aPKC and PAR-3. Dev Cell (2007) 2.83
Numb is a suppressor of Hedgehog signalling and targets Gli1 for Itch-dependent ubiquitination. Nat Cell Biol (2006) 2.40
Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res (2007) 2.25
Crossing paths with Notch in the hyper-network. Curr Opin Cell Biol (2007) 2.20
Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Cancer (2008) 2.11
Polo inhibits progenitor self-renewal and regulates Numb asymmetry by phosphorylating Pon. Nature (2007) 1.83
aPKC-mediated phosphorylation regulates asymmetric membrane localization of the cell fate determinant Numb. EMBO J (2007) 1.81
Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration. J Biol Chem (2007) 1.57
High levels of Notch signaling down-regulate Numb and Numblike. J Cell Biol (2006) 1.47
In vivo evidence for the role of CD44s in promoting breast cancer metastasis to the liver. Am J Pathol (2007) 1.25
Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer (1999) 1.19
Phosphorylation of Numb family proteins. Possible involvement of Ca2+/calmodulin-dependent protein kinases. J Biol Chem (2005) 1.09
Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy. Cancer J (2007) 1.04
Phosphorylation of Numb regulates its interaction with the clathrin-associated adaptor AP-2. FEBS Lett (2006) 0.89
Prostate tumor cells infected with a recombinant influenza virus expressing a truncated NS1 protein activate cytolytic CD8+ cells to recognize noninfected tumor cells. J Virol (2006) 0.88
Taxol increases the amount and T cell activating ability of self-immune stimulatory multimolecular complexes found in ovarian cancer cells. Cancer Res (2007) 0.88
Sensitivity of undifferentiated, high-TCR density CD8+ cells to methylene groups appended to tumor antigen determines their differentiation or death. Cancer Res (2005) 0.83
Induction of tumor-reactive CTL by C-side chain variants of the CTL epitope HER-2/neu protooncogene (369-377) selected by molecular modeling of the peptide: HLA-A2 complex. J Immunol (2002) 0.82
Novel natural immunogenic peptides from Numb1 and Notch1 proteins for CD8+ cells in ovarian ascites. Int J Oncol (2007) 0.80
Unfavorable prognostic value of CD24 expression in sections from primary and relapsed ovarian cancer tissue. Int J Gynecol Cancer (2006) 0.79
A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science (2002) 42.78
Landscape of transcription in human cells. Nature (2012) 20.18
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood (2008) 4.61
Targets and dynamics of promoter DNA methylation during early mouse development. Nat Genet (2010) 4.27
Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest (2008) 4.13
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res (2009) 3.30
Global analysis of the Deinococcus radiodurans proteome by using accurate mass tags. Proc Natl Acad Sci U S A (2002) 3.15
Calmodulin-kinases: modulators of neuronal development and plasticity. Neuron (2008) 3.14
Acute toxicity and biodistribution of different sized titanium dioxide particles in mice after oral administration. Toxicol Lett (2006) 3.06
A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release. Endocrinology (2008) 3.04
Childhood air pollutant exposure and carotid artery intima-media thickness in young adults. Circulation (2012) 2.51
Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol (2005) 2.43
Estrogen receptor (ER)-beta reduces ERalpha-regulated gene transcription, supporting a "ying yang" relationship between ERalpha and ERbeta in mice. Mol Endocrinol (2003) 2.38
Linking promoters to functional transcripts in small samples with nanoCAGE and CAGEscan. Nat Methods (2010) 2.30
Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother (2009) 2.25
Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol (2010) 2.12
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol (2009) 2.12
Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12
NLRX1 negatively regulates TLR-induced NF-κB signaling by targeting TRAF6 and IKK. Immunity (2011) 2.10
For breast cancer prognosis, immunoglobulin kappa chain surfaces to the top. Clin Cancer Res (2012) 2.09
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest (2009) 2.08
Lost in Translation: Obstacles to Translational Medicine. J Transl Med (2004) 2.03
Disruption of murine Mus81 increases genomic instability and DNA damage sensitivity but does not promote tumorigenesis. Mol Cell Biol (2005) 2.00
Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res (2012) 1.94
A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology (2007) 1.91
Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer (2010) 1.90
A tripartite paternally methylated region within the Gpr1-Zdbf2 imprinted domain on mouse chromosome 1 identified by meDIP-on-chip. Nucleic Acids Res (2010) 1.83
Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol (2007) 1.80
DNA methylation in the arginase-nitric oxide synthase pathway is associated with exhaled nitric oxide in children with asthma. Am J Respir Crit Care Med (2011) 1.79
The impact of breastfeeding on nasopharyngeal microbial communities in infants. Am J Respir Crit Care Med (2014) 1.78
HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res (2008) 1.77
Deep sequencing analyses of low density microbial communities: working at the boundary of accurate microbiota detection. PLoS One (2012) 1.76
Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol (2004) 1.68
Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res (2005) 1.68
Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol (2003) 1.67
FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia. Blood (2008) 1.67
HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res (2006) 1.65
Monoclonal antibodies for cancer immunotherapy. Lancet (2009) 1.64
Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res (2013) 1.63
Associations between pathogens in the upper respiratory tract of young children: interplay between viruses and bacteria. PLoS One (2012) 1.63
BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells. Cancer Res (2004) 1.58
Regulation of axonal extension and growth cone motility by calmodulin-dependent protein kinase I. J Neurosci (2004) 1.57
TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res (2013) 1.56
Time-dependent translocation and potential impairment on central nervous system by intranasally instilled TiO(2) nanoparticles. Toxicology (2008) 1.56
Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol Cancer Ther (2014) 1.56
Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia (2004) 1.56
Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells. Stem Cells (2006) 1.56
Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol (2003) 1.55
Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8⁺ T cells. Clin Cancer Res (2011) 1.54
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature (2016) 1.52
Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice. Cancer Res (2007) 1.51
Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol (2006) 1.49
Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res (2005) 1.49
Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget (2014) 1.49
Surface chemistry and aspect ratio mediated cellular uptake of Au nanorods. Biomaterials (2010) 1.48
Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res (2006) 1.48
Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma. J Invest Dermatol (2005) 1.48
Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother (2007) 1.47
Vaccination of cytotoxic T lymphocyte-directed peptides elicited and spread humoral and Th1-type immune responses to prostate-specific antigen protein in a prostate cancer patient. J Immunother (2005) 1.47
Serum progesterone level effects on the outcome of in vitro fertilization in patients with different ovarian response: an analysis of more than 10,000 cycles. Fertil Steril (2012) 1.46
Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother (2011) 1.46
Sws1 is a conserved regulator of homologous recombination in eukaryotic cells. EMBO J (2006) 1.46
Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis (2006) 1.46
Human papillomavirus in non-oropharyngeal head and neck cancers: a systematic literature review. Head Neck Pathol (2012) 1.45
Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res (2006) 1.45
Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck (2010) 1.45
Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther (2012) 1.44
Long-term renal changes in the liver-specific glucokinase knockout mouse: implications for renal disease in maturity-onset diabetes of the young 2. Transl Res (2010) 1.44
Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals. Vaccine (2011) 1.43
Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity. Cancer Res (2006) 1.43
Increased gap density predicts weakness of the epithelial barrier in vivo by confocal laser endomicroscopy in indomethacin-induced enteropathy. Dig Dis Sci (2014) 1.41
Blockade of NOX2 and STIM1 signaling limits lipopolysaccharide-induced vascular inflammation. J Clin Invest (2013) 1.40
Polyclonality of BRAF mutations in acquired melanocytic nevi. J Natl Cancer Inst (2009) 1.40
The associations of Janus kinase-2 (JAK2) A830G polymorphism and the treatment outcomes in patients with acute myeloid leukemia. Leuk Lymphoma (2010) 1.40
Selective targeting of gold nanorods at the mitochondria of cancer cells: implications for cancer therapy. Nano Lett (2010) 1.40
HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol (2002) 1.39
Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. Int J Cancer (2011) 1.39
Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res (2010) 1.37
Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. PLoS One (2010) 1.36
Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol (2003) 1.36
Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer (2013) 1.35
HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res (2005) 1.35
Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res (2007) 1.35
Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res (2008) 1.33
Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin Cancer Res (2005) 1.32
Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int J Cancer (2006) 1.32
Analysis of CaM-kinase signaling in cells. Cell Calcium (2011) 1.30
Multiple roles of PPARalpha in brown adipose tissue under constitutive and cold conditions. Genes Cells (2009) 1.30
Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. Stem Cells (2008) 1.28
Potential neurological lesion after nasal instillation of TiO(2) nanoparticles in the anatase and rutile crystal phases. Toxicol Lett (2008) 1.27
The genome landscape of ERalpha- and ERbeta-binding DNA regions. Proc Natl Acad Sci U S A (2008) 1.27
Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res (2005) 1.27
Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res (2011) 1.26
A caveolae-targeted L-type Ca²+ channel antagonist inhibits hypertrophic signaling without reducing cardiac contractility. Circ Res (2012) 1.26
CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. J Natl Cancer Inst (2010) 1.26
Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer. Surgery (2006) 1.25
A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. J Immunol Methods (2005) 1.25